Table 2. Comparison between ranibizumab and bevacizumab groups.

Parameters	Ranibizumab (n=26)	Bevacizumab (n=33)	P
Final logMAR (Snellen equivalent)	0.28±0.24 (20/40)	0.48±0.08 (20/60)	0.07
logMAR change	-0.35±0.08	-0.29±0.09	0.66
Equivalent lines/ETDRS letters gained	3.5 lines/17.5 ETDRS letters	2.9 lines/14.5 ETDRS letters
Eyes gaining >3 lines	13/26 (50%)	16/33 (48%)	0.91
Eyes losing >3 lines	0/26	2/33 (6%)	0.20
Central subfield (µm) change	-186±38 (n=22)	-212±40 (n=24)	0.69
Residual intraretinal fluid	17/26 (65%)	13/28 (46%)	0.16
Residual subretinal fluid	0/26	4/28 (14%)	10.14
IOP (mmHg) change	0.94±0.96	-0.52±0.67	0.22
Days between injections	94±21.1	103.8±10.5	0.78

IOP: Intraocular pressure. ¹Yate's correction was used due to low expected frequencies. The mean±SE is shown.